Mastering the art of patient-focused treatment

Taking on the challenges inherent in today’s cancer treatments isn’t easy…but we’re up for it. We are Athenex—a team of scientists, investigators, and innovators driven by the patients we serve. Our robust investigational pipeline of novel small molecule, biologic, and cellular therapies is focused on both improving outcomes and improving the cancer treatment experience for patients around the world.

Program

Drug candidate

Indication

Pre-clinical

Phase 1

Phase 2

Phase 3

Orascovery
(P-gp inhibitor [encequidar] + chemoRx agents)

Metastatic breast cancer

Angiosarcoma

Oral topotecan + encequidar

Solid tumors

Oral eribulin + encequidar

Solid tumors

Dual Inhibition

ATNX-04 (CYP / P-gp)

Multiple tumors

Src Kinase Inhibition

Tirbanibulin (KX2-391) ointment

Actinic keratosis

Psoriasis

Skin Cancers

Tirbanibulin (KX2-391) oral

Liquid tumors / Ovarian cancer

KX2-361 (KX-02)

Glioblastoma

TCR-T Immunotherapy

TAEST16001

Multiple tumors

Arginine Deprivation Therapy

(PT-01) Pegtomarginase

Multiple tumors

Posted pipeline was current on August 5, 2019. Pipeline may not reflect changes in phase of development after August 5, 2019.

*Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
**Collaboration with Eli Lilly and Company, makers of ramucirumab.

Clinical Platform

Orascovery
(P-gp inhibitor [encequidar] + chemoRx agents)

Oral paclitaxel + encequidar*


Metastatic breast cancer

PHASE 3

Angiosarcoma

PHASE 2
PHASE 1
PHASE 1

Oral topotecan + encequidar


Solid tumors

PHASE 1

Oral eribulin + encequidar


Solid tumors

PRE-CLINICAL

Clinical Platform

Dual Inhibition

ATNX-04 (CYP / P-gp)


Multiple tumors

PRE-CLINICAL

Clinical Platform

Src Kinase Inhibition

Tirbanibulin (KX2-391) ointment


Actinic keratosis

PHASE 3

Psoriasis

PHASE 1

Skin Cancers

PRE-CLINICAL

Tirbanibulin (KX2-391) oral


Liquid tumors / Ovarian cancer

PHASE 1

KX2-361 (KX-02)


Glioblastoma

PHASE 1

Clinical Platform

TCR-T Immunotherapy

TAEST16001


Multiple tumors

PRE-CLINICAL

Clinical Platform

Arginine Deprivation Therapy

(PT-01) Pegtomarginase


Multiple tumors

PRE-CLINICAL

Posted pipeline was current on August 5, 2019. Pipeline may not reflect changes in phase of development after August 5, 2019.

*Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
**Collaboration with Eli Lilly and Company, makers of ramucirumab.

Relevant medical materials for download

Poster Presentations


YU KM, PANG TP, CUTLER M, LAU JY, LO TW, LEUNG TY.

Design, engineering, and characterization of a novel long-acting (pegylated) single isomer human arginase for arginine-depriving anti-cancer treatment. Poster presented at: American Society of Clinical Oncology; May 31-June 4, 2019; Chicago, IL.

UMANZOR G, VASSALLO RH, CASTRO MAC, ET AL.

An open label, randomized, multicenter, phase 3 registrational study to determine the safety, tolerability, and tumor response of oral paclitaxel and encequidar (formerly HM30181A) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC) (NCT-02594371). Poster presented at: American Society of Clinical Oncology; May 31-June 4, 2019; Chicago, IL.

JIMENO A, OPYRCHAL, DIAMOND JR, ET AL.

A phase 1 study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor encequidar (NTC02250157). Poster presented at: American Society of Clinical Oncology; May 31-June 4, 2019; Chicago, IL.

DAI MS, CHAO TY, CHAO TC, ET AL.

1084- Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients. Poster presented at: American Society of Clinical Oncology; May 31-June 4, 2019; Chicago, IL.

DAI MS, CHAO TY, CHAO TC, ET AL.

An open-label, single-arm pharmacokinetic study of oral paclitaxel and HM30181 in metastatic breast cancer patients. Poster presented at: European Society for Medical Oncology; October 19-23, 2018; Munich, Germany.

JACKSON C, DEVA S, BAYSTON K, ET AL.

An open label, randomised cross-over bioavailability and extension study of oral paclitaxel and HM30181 (Oraxol) compared to weekly intravenous paclitaxel 80mg/m2 in advanced solid tumours. Poster presented at: European Society for Medical Oncology Asia; November 17-19, 2017; Singapore.

JACKSON C, BAYSTON K, MCLAREN B, ET AL.

An open label, randomised cross-over bioavailability study of Oral Paclitaxel (Oraxol) compared to intravenous paclitaxel 80mg/m. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 5, 2016; Chicago, IL.

MA WW, AZAD NS, LAM ET, ET AL.

A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of Oraxol in patients with advanced malignancies. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 4, 2018; Chicago, IL.

CUTLER MJ, BELKO KE, BU Y, ET AL.

Effective preclinical management of angiosarcoma with oral paclitaxel. Poster presented at: the American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; Atlanta, GA.

JACKSON C, DEVA S, BAYSTON K, ET AL.

An open label, randomised cross-over bioavailability and extension study of Oral Paclitaxel and HM30181 (Oraxol) compared to weekly intravenous paclitaxel 80 mg/m2 in advanced solid tumours. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1-5, 2018; Chicago, IL.